We help clinicians

Win the toughest battles

A new landscape of information

Complex diseases, and their response to treatment, are heterogeneous. AIQ products will help you understand your patients' response to treatment sooner and at a more comprehensive level than is currently possible with other technologies. AIQ broadens the information landscape available to clinicians, using data that are reliable, proven and actionable.

How do our solutions help you?

Every day, you fight to treat constantly adapting diseases under pressure to reduce treatment costs. Our platform supplies intelligence, analytics, and insights you cannot get from other systems or tools. We help you make a real difference for your patients, every day. We help you win the tough battles.

01

Increase understanding of disease

For complex diseases, intra-patient response is heterogeneous.

02

Make better treatment decisions

Heterogeneous treatment response impacts clinical outcomes.

03

Assess treatment effectiveness earlier

AIQ products will help you understand your patient's response to treatment sooner and more comprehensively.

04

Extend your patients' lives

Data from AIQ products are reliable, proven, and actionable, so you can make a real difference for your patients.

01

Increase understanding of disease

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. 

Learn more ›

02

Make better treatment decisions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. 

Learn more ›

03

Assess treatment effectiveness earlier

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. 

Learn more ›

04

Extend your patients' lives

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. 

Learn more ›

QTBI Reveals an alternate treatment approach

Case study
Diagnosis

Prostate cancer metastatic to bone

Current treatment

Nonsteroidal antiandrogen medication

Clinical symptoms

Clinical indicators, including PSA, stable for 12 months following treatment; however, at week 54 PSA began to climb and patient reported new pain in pelvis

Standard imaging analysis

Single lesion on pelvis has increased in size

Clinical decision

Given new pain with increase in PSA levels, a decision was made to switch therapy to a chemotherapy medication

Outcome

Significant clinical progression within 8 weeks

Analysis using QTBI

Patient's treatment response evaluated retroactively with QTBI at 12, 54, and 62 weeks into treatment. At 12 weeks there was a substantial decrease in tumor burden with majority of lesions improving on therapy.

Repeat QTBI at week 54 shows progressive disease in the left pelvis with remainder of disease stable to improved.

A subsequent QTBI 8 weeks after switching to chemotherapy medication shows not only ongoing progression in the left pelvis, but also disease progression among many of the lesions which were still responding to the nonsteroidal antiandrogen medication at 54 weeks.

potential alternate approach

Had QTBI information been available, a decision to give localized radiation to the left pelvis could have been made allowing the patient to maintain disease control on his nonsteroidal antiandrogen therapy. Because most lesions were still responding well to that therapy, this approach may have prevented the negative outcomes subsequently observed.

Interested in knowing more? We'd love to show you our revolutionary platform.

Contact us for a demo